期刊
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
卷 18, 期 4, 页码 603-618出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.beha.2005.01.005
关键词
multiple myeloma; autologous stem-cell transplantation; allogeneic stem-cell transplantation; reduced-intensity allogeneic transplantation
类别
In patient with newly diagnosed multiple myeloma (MM), randomized studies have shown that autologous stem-cell transplantation (ASCT) is superior to conventional chemotherapy, and ASCT is now standard care, at least for younger patients. The best conditioning regimen is melphalan 200 mg/m(2), and the best stem-cell source is unselected peripheral progenitor cells. Recent results of the IFM94 trial show that double ASCT is superior to single ASCT at least in patients who do not achieve a 90% response after one transplant. By combining biologic markers (beta(2)-microglobulin, albumin) and genetic markers (hypodiploidy, chromosome 13 deletion) it is possible to accurately predict prognosis after ASCT The results of allogeneic SCT remain disappointing due to a high transplant mortality. Strategies combining ASCT and reduced-intensity allogeneic SCT are currently being studied.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据